Epcoritamab plus GDP chemotherapy for relapsed large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests epcoritamab combined with GDP chemotherapy to treat adults whose large B-cell lymphoma has come back or did not respond to prior treatment. It aims to improve how safely and effectively the disease can be controlled after standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to give consent (including permission to use medical records).
- Have relapsed or refractory CD20-positive large B-cell lymphoma proven by pathology, and it must show on PET scan with measurable active disease.
- Have had at least one prior course of systemic (whole-body) lymphoma treatment, and your lymphoma must have relapsed or progressed within set timeframes after first-line chemo.
- Be well enough for treatment (ECOG 0–2) and have adequate blood, kidney, and liver function based on screening labs.
- Be eligible for stem cell transplant or CAR T-cell therapy if your doctor thinks that’s appropriate (even though you may not have had it yet).
- Have tumor tissue available (archived within 2 years, or a standard-of-care biopsy); fine-needle samples usually don’t count.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This trial tests a combination of a lower dose of the immunotherapy drug epcoritamab with standard chemotherapy (GemOx) for people with a type of lymphoma called DLBCL that has come back or not responded to previous treatment. The goal is to see if this combination can help get the lymphoma under control before a stem cell transplant (using your own cells).
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Hear when a new Relapsed Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.